Racial Disparities in Prostate Cancer Outcomes Following Radiation for Men Diagnosed and Treated in an Equal Access Military Healthcare System

C. A. Smith,W. K. Skinner,I. L. Rosner,C. Kuo,Y. Chen,S. P. Stroup,T. C. Brand,J. R. Sterbis,C. Porter,J. Cullen

DOI: https://doi.org/10.1016/j.ijrobp.2017.06.513

2017-01-01

Abstract:Poorer prostate cancer (CaP) outcomes among black men have been noted in a number of studies. This disparity in outcomes across race has been attributed to biology, treatment type, aggressiveness, lifestyle, and socioeconomic factors. Comparisons in CaP outcomes by race within equal access healthcare systems (both the DOD and VA) have indicated that black and white men experience equivalent outcomes. Recent studies show nuances in treatment outcome by the stage/risk group of prostate cancer, a factor that has not previously been well evaluated, possibly due to a low total number of black patients in most longitudinal patient cohorts. In this study, we examine a subset of DOD military health care beneficiaries enrolled in the Center for Prostate Disease Research (CPDR) Multicenter National Database to study the role of race as a predictor of CaP outcomes following radiation therapy (RT) with stratification by current NCCN risk groupings. This retrospective cohort study examined all patients undergoing external beam radiation therapy (EBRT) or brachytherapy (BRY) for treatment of prostate cancer between January 1989 and December, 2016. Patient with less than 2 years follow-up were excluded. PSA recurrence was defined per the Phoenix 2006 consensus definition as a rise of 2 ng/mL above the PSA nadir. Race was based on patient self-report (Black versus White). Risk stratification was based on the 2017 NCCN guidelines. The primary study outcome was Biochemical progression-free survival (BPFS), modeled using Kaplan Meier (KM) estimation curve analysis, both unadjusted and adjusted for NCCN risk group. KM Models were run separately for men who underwent EBRT versus BRY. A total of 1969 men were eligible for the study with over one quarter Black, and an overall median follow-up time and age at RT of 6.7 and 69.8 years for EBRT and 6.9 and 65.4 years for BRY, respectively. There was no significant difference in in the NCCN risk stratification distributions by race (P = 0.1404). There was no significant difference in BPFS for Black versus white men, overall or within each NCCN risk group (low, intermediate, and high) (log-rank P = 0.12, 0.35, 0.67, respectively). Moreover, there was no significant difference in BPFS of black and white patient’s by either treatment modality including EBRT and brachytherapy (log-rank P = 0.77 and 0.96, respectively). Black patients experience comparable CaP outcomes following both types of RT in this racially diverse equal access health care system, even when considering clinical risk stratum. This study had a limited follow-up time of less than 7 years, preventing examination of longer term study endpoints such as metastasis and CaP-specific mortality. However, subsequent work will examine overall survival, with consideration of patient comorbidity profiles.